Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands by Meijboom, M. J. et al.
  
 University of Groningen
Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in
The Netherlands
Meijboom, M. J.; Rozenbaum, M. H.; Benedictus, A.; Luytjes, W.; Kneyber, M. C. J.; Wilschut,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2012
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Meijboom, M. J., Rozenbaum, M. H., Benedictus, A., Luytjes, W., Kneyber, M. C. J., Wilschut, J. C., ...
Postma, M. J. (2012). Cost-effectiveness of potential infant vaccination against respiratory syncytial virus
infection in The Netherlands. Vaccine, 30(31), 4691-4700. https://doi.org/10.1016/j.vaccine.2012.04.072
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the





























hVaccine 30 (2012) 4691– 4700
Contents lists available at SciVerse ScienceDirect
Vaccine
jou rn al h om epa ge: www.elsev ier .com/ locate /vacc ine
ost-effectiveness  of  potential  infant  vaccination  against  respiratory  syncytial
irus  infection  in  The  Netherlands
.J.  Meijbooma,b, M.H.  Rozenbauma, A.  Benedictusb, W.  Luytjesc, M.C.J.  Kneyberd,e,  J.C.  Wilschut f,
. Haka,b,∗,  M.J.  Postmaa
Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands
Department of Epidemiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands
National Institute of Public Health & the Environment, former Netherlands Vaccine Institute (NVI), Bilthoven, The Netherlands
Department of Pediatric Intensive Care, Beatrix Children’s Hospital, University Medical Center Groningen, Groningen, The Netherlands
Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands
Department of Medical Microbiology – Molecular Virology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 30 August 2011
eceived in revised form 11 April 2012
ccepted 21 April 2012





odeling policy making Netherlands
nfants
a  b  s  t  r  a  c  t
Introduction:  Respiratory  syncytial  virus  (RSV)  infection  is one  of  the  major  causes  of respiratory  illness
in infants,  infecting  virtually  every  child  before  the  age  of  2 years.  Currently,  several  Phase  1 trials  with
RSV  vaccines  in  infants  are  ongoing  or have  been  completed.  As yet, no  efﬁcacy  estimates  are  available
for  these  vaccine  candidates.  Nevertheless,  cost-effectiveness  estimates  might  be  informative  to  enable
preliminary  positioning  of  an  RSV  vaccine.
Methods:  A  decision  analysis  model  was developed  in which  a Dutch  birth  cohort  was  followed  for  12
months.  A  number  of  potential  vaccination  strategies  were  reviewed  such  as vaccination  at  speciﬁc  ages,
a two-  or  three-dosing  scheme  and  seasonal  vaccination  versus  year-round  vaccination.  The impact  of the
assumptions  made  was  explored  in  various  sensitivity  analyses,  including  probabilistic  analysis.  Outcome
measures  included  the  number  of  GP  visits,  hospitalizations  and  deaths,  costs,  quality-adjusted  life years
and incremental  cost-effectiveness  ratios  (ICERs).
Results:  Currently,  without  vaccination,  an  annual  number  of 28,738  of RSV-related  GP  visits,  1623  hos-
pitalizations,  and  4.5  deaths  are  estimated  in  children  in  the  age  of  0–1 year.  The  total  annual  cost  to
society  of RSV  in  the  non-vaccination  scenario  is D  7.7  million  (95%CI:  1.7–16.7)  and the  annual  disease
burden  is estimated  at 597  QALYs  (95%CI:  133–1319).  In  case  all infants  would  be  offered  a  potentially
safe  and  effective  3-dose  RSV  vaccination  scheme  at the  age  of  0, 1  and  3  months,  the  total  annual  net
costs  were  estimated  to  increase  to  D 21.2  million,  but 544  hospitalizations  and  1.5 deaths  would  be
averted.  The  ICER  was  estimated  at D 34,142  (95%CI:  D  21,652–D  87,766)  per  QALY  gained.  A  reduced
dose  schedule,  seasonal  vaccination,  and  consideration  of  out-of-pocket  expenses  all  resulted  in more
favorable  ICER  values,  whereas  a reduced  vaccine  efﬁcacy  or  a delay  in  the  timing  of  vaccination  resulted
in less  favorable  ICERs.
Discussion:  Our  model  used  recently  updated  estimates  on  the  burden  of  RSV  disease  in  children  and
it included  plausible  utilities.  However,  due  to the  absence  of  clinical  trial data,  a number  of  crucial
assumptions  had to be made  related  to  the  characteristics  of  potential  RSV  vaccine.  The outcomes  of our
modeling  exercise  show  that  vaccination  of infants  against  RSV might  be  cost-effective.  However,  clinical
trial  data  are  warranted.
. IntroductionRespiratory syncytial virus (RSV) infection is one of the major
auses of respiratory illness among infants, infecting virtually
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every child before the age of 2 years [1,2]. The epidemiology of
RSV shows a recurrent seasonal incidence pattern, similar to that
of inﬂuenza, with an incidence peak in the winter months [3–7].
A previous RSV-infection may  provide transient protection but
does not prevent subsequent infections later on in life [2,8,9].  The
course of many RSV-related episodes is mild but in a number of
cases it is associated with a lower respiratory tract infection [1].  In
approximately 1–2% of the cases, RSV-infection may  lead to pneu-
monia and bronchiolitis requiring hospitalization [1,2,5,6,10].
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ongenital heart disease (CHD) and bronchopulmonary dys-
lasia (BPD). RSV-induced bronchiolitis is associated with severe
pisodes of recurrent wheezing in infancy and asthma in 8–70%
f cases [11–13].  In school-aged children, wheeze is no longer
ssociated with a history of RSV-hospitalization [11,12]. The low
ncidence of RSV-related mortality makes it difﬁcult to obtain con-
istent data on excess RSV-mortality in epidemiological studies.
nly in a very small number of studies RSV-mortality was studied
rospectively. Indeed, the majority of studies used a retrospective
tudy design and could not demonstrate signiﬁcant rates of RSV-
ssociated mortality [3]. Mortality was primarily observed in the
oungest children, aged <12 months. Estimates range from 0.03 per
00,000 to 5.3 per 100,000 population. The Dutch National Institute
or Public Health and the Environment (RIVM) reports a mortality
ate of 0.03 per 100,000 for the total population corresponding to a
otal number of 4.5 deaths annually due to RSV (equaling 2.78 per
00,000 infants 0–12 months of age). This is in line with estimates
rom the UK, where RSV-incidence patterns are similar to those
n the Netherlands [10,14]. In the UK, RSV-associated excess
ortality has been estimated at 2.9 deaths per 100,000 infants per
ear [14].
Treatment options for severe cases of RSV are limited. Hospi-
alization occurs when oxygen supplementation or intravenous
uids as well as nasogastric feeding is required [15]. Antiviral
rugs such as ribavirin are indicated only in infants with a com-
romised immune system. Primary prophylaxis with palivizumab
r RSV-immunoglobulin is expensive, potentially not highly cost-
ffective and should be provided restrictively. Yet, despite that
alivizumab prophylaxis was not judged cost-effective in the
etherlands, conditional reimbursement was granted and more
han 1800 Dutch prematurely born infants receive it annually
16].
In the light of the burden of disease and the potential cost-
ffectiveness of the possible prophylactic regimens, ideally a
accine should be available that protects infants at risk. Given
he fact that the majority of hospitalizations occur before the
ge of 6 months, this vaccine should induce protective immu-
ity at a very early age. The development of an RSV-vaccine
or children has been hampered by the disastrous outcome
f a clinical trail with formalin-inactivated whole-virus RSV-
accine in the 1960s. It appeared that vaccination with the
accine did not confer protection, but rather primed the vac-
inees for enhanced disease upon subsequent exposure to live
SV, leading to the death of two children [17]. The enhanced
isease was linked to severe immunopathology as a result of
 Th2-type cellular immune response induced by the vaccine,
s well as the induction non-neutralizing antibodies [17–19].
urrently, several Phase 1 trials with live attenuated vaccines
gainst RSV infection in infants are running or have been
ompleted (www.clinicaltrials.gov, accessed March, 2011). Such
ive attenuated vaccines are likely to induce a more balanced
mmune response as compared to unadjuvanted inactivated vac-
ines.
The number of papers modeling RSV vaccination is limited and
ll have become available rather recently. One study performed in
pain in 2009 reviewed potential vaccination strategies in infants
1 yr of age and in the Netherlands vaccination was  analyzed in
nfants <2 yrs of age [20,21].  This paper presents an update of our
revious cost-effectiveness estimate of RSV-vaccination of infants
n the Netherlands [21]. In addition to our previously reported
odel, we now include quality-of-life estimates in the model
aking it possible to provide an estimate of the overall cost-ffectiveness of infant vaccination against RSV, expressed in D per
uality-adjusted life year (QALY) gained. Furthermore, epidemio-
ogical data were updated, based on the most recent information
3,4]. 30 (2012) 4691– 4700
2.  Methods
2.1. Model
A Markov cohort model was  developed in the decision ana-
lytic software package TreeAge Pro 2009 (see www.treeage.com for
more information) and the model was  analyzed using Monte Carlo
simulation methods. The model is currently a static model, assum-
ing a constant force of infection and no herd-immunity effects. The
Markov cohort is a monthly Dutch birth cohort, which is followed
for 12 months with a cycle length of one month.
In the analyses, a cohort of 180,000 newborns (approximating
the Dutch birth cohort) is followed twice: once as a mainly vac-
cinated cohort and once as an unvaccinated cohort. The model
outline is shown in Fig. 1. All newborns begin in the state
“naïve/susceptible” at an age of 0 months. Each month the cohort
faces a risk (transition probability) of a symptomatic RSV infec-
tion. This risk is dependent on the season (calendar month) and
the age of the cohort (in months). A symptomatic infection may
lead to health-care utilization such as a GP visit or hospitalization.
Due to insufﬁcient data on the actual number of symptomatic RSV
infections, the model was  calibrated to the number of GP visits.
After having gone through a symptomatic RSV infection, the pro-
portion of the cohort moves to either one of the states “acquired
immunity” or “death”. Dependent on the vaccination scenario, the
cohort faces a monthly probability of being vaccinated. Vaccinated
members of the cohort move to the state “vaccinated”, which
represents either full or partial immunity from symptomatic RSV
infection, dependent on the speciﬁc parameter values for vaccine
efﬁcacy.
2.2. Baseline disease risks
In the Netherlands, infants with a clinical RSV infection are
generally taken to a general practitioner (GP) by their parents or
caretakers. The GP decides whether to refer the patient to a hospital.
Hospitalized children may  either be discharged or die. Estimating
the magnitude of the health burden of RSV is challenging because a
signiﬁcant proportion of RSV-infections are asymptomatic, the size
of RSV-epidemics varies across seasons, and outbreaks of RSV often
coincide or overlap with outbreaks of inﬂuenza with comparable
symptomatology [3,7,10]. Despite high incidence rates, mortality
from RSV is very low in West-European countries, which hampers
obtaining reliable mortality rates. Infants presented at the hospital
with relevant symptoms are very often tested for RSV and there-
fore it is assumed that hospitalization and mortality rates are rather
reliable for this hospitalized population. This is probably untrue
for the GP data as patients are most often not clinically tested for
RSV. Several authors have assessed the health burden from RSV.
An overview of these assessments is presented and the result is
discussed in Appendix A. The data from which the transition prob-
abilities in the model are derived, are presented in Table 1.
Several authors have demonstrated an association between
RSV-infection in infancy and chronic respiratory morbidity in
childhood, such as asthma and episodes of recurrent wheezing
[1,11–13]. However, it remains uncertain whether there indeed
is a causal relationship between RSV-hospitalization and chronic
respiratory morbidity. In addition, there is a wide range of esti-
mates for both the proportion of RSV-hospitalizations associated
with sequelae, and the duration and severity of the symptoms
[1,13,22,23]. Because of the uncertainty in the association between
RSV-infection and chronic respiratory morbidity later in life it was
decided to model the occurrence of chronic respiratory morbidity
as an alternative scenario. The assumptions for this scenario are
presented in Table 1 and discussed in Appendix A.







Dig. 1. Markov model for RSV vaccination in infants. A square denote decision branc
odes.
.3. Vaccine efﬁcacy and vaccination strategiesAs RSV-vaccines are still under development, assumptions had
o be made regarding vaccine efﬁcacy and dosing. Because RSV-
accination is likely to be considered for inclusion in the National
able 1
ata used in the economic model. An overview of the consulted literature and supporting
Health burden related to RSV Mean or
Excess GP visits per 100 K/y (age 0–12 m/o) 16,000 (
Proportion of GP visits with bronchi(oli)tis 35% 
Excess  hospitalizations per 100 K/y (age 0–12 m/o) 900
Excess mortality per 100 K/y (0–12 m/o) 2.5 
Duration of chronic respiratory morbidity (y) 5 
Probabilities of events in age group 0–12 months old (based on the
health burden summarized above)
RSV-related GP visit 0.160 
RSV-related hospitalization (as % of GP visits) 0.05625
ICU  admissions (as % of hospitalizations) 0.02606
RSV-related mortality (as % of hospitalizations) 0.00277
RSV  hospitalizations leading to chronic respiratory morbidity 0.30 
Costs  associated with RSV-infections
Cost of GP visit D 22.17
Cost  of RSV-hospitalization D 3749.
Productivity loss per GP visit (workdays) 0.25 
Productivity loss per hospitalization (workdays) 2.00 
Cost  of lost workday (not corrected for productivity elasticity) D 250.4
Productivity elasticity 30–45% 
QALY  decrements
GP-treated RSV bronchi(oli)tis 0.01 
RSV  hospitalization 0.04 
Chronic  respiratory morbidity 0.08 
Parameters related to vaccination program
Level of protection against infection scenario
Vaccination coverage rate 0.96 
Price of vaccine per dose D 37.50
Price of administration costs D 5.00 
Proportion of infections covered under various vaccination scenarios
Year-round vaccination of all <3 m/o 0.62 
Vaccination in October, age groups 3–6 m/o  0.176 
Vaccination in November, age groups 3–6 m/o  0.207 
Vaccination in November, age groups 3–9 m/o  0.270 
Vaccination in November, age groups 3–12 m/o  0.301 accination vs no vaccination). Circles represent chance nodes. Triangles denote end
Immunization Program (NIP) in the Netherlands as well as in other
countries, a vaccination strategy was considered in which all infants
of a certain age are eligible for vaccination. Given the disease burden
in the ﬁrst year, vaccination was considered as early as possible.
For a three-dose schedule vaccination was  considered for infants
 calculations is provided in Appendix A.
 range Distribution Reference
9400 as alt. scen.) n/a [3]
Beta (SD = 0.035) [3]
n/a [4]
n/a [14,15]
Gamma (sd = 0.6) [1,11]
See Appendix A for details
Beta (SD = 0.0160)
 Beta (SD = 0.005625) calc. from incidence data
 Beta (SD = 0.002606)
8 Beta (SD = 0.000278) calc. from incidence data
Beta (SD = 0.008) [1,11]
 Fixed [27]





Gamma (SD = 0.001) [25]
Gamma (SD = 0.004) [25]
Gamma (SD = 0.007) [25,33]
 dependent Beta NVI, p.c.
Beta (SD = 0.096) NVI, p.c.
 Fixed NVI, p.c.
Fixed NVI, p.c.
Beta (SD = 0.062) [5,6]
Beta (SD = 0.0176) [5,6]
Beta (SD = 0.0207) [5,6]
Beta (SD = 0.0270) [5,6]
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t the ages of 0, 1 and 3 months with vaccine efﬁcacies of 30%, 60%
nd 75%, respectively. For a two-dose schedule, vaccination was
onsidered at 0 and 3 month of age with vaccine efﬁcacies of 30%
nd 70%. On immunological grounds, it is assumed that a three-
ose schedule would result in a somewhat higher vaccine efﬁcacy
han a two-dose schedule, and that a one-dose schedule would be
nsufﬁcient to provide adequate protection. In accordance with the
overage rate of the Dutch NIP, coverage for the total cohort was
ssumed to equal 96%. In the base case analysis, no waning effect
elated to the vaccine efﬁcacy was taken into account.
In scenario analyses, several alternative scenarios were
xplored. A “seasonal” strategy was explored in which vaccina-
ion takes place only in the winter months, in order to protect the
ge groups at risk against the seasonal incidence peak. This would
esult in a lower coverage rate for the total birth cohort. However, as
he approach is targeted at a high-risk condition, cost-effectiveness
ay  be expected to be better. The age at which the vaccination
chedule was completed was varied, and the effect of reaching a
0% vaccine efﬁcacy already after the second dose was investi-
ated. Also, the protective effect of vaccination wanes over time
nd therefore a linear and a plateau waning effect was explored
n the analyses to review the potential impact on the ICER. The
ime period to look at the waning effect was ten years. The base-
ine disease risks with respect to the number of RSV-related GP
isits was varied (9400 per 100,000 children <12 m/o  per year) as
as the occurrence of chronic respiratory morbidity. In addition to
he average cost-effectiveness of immunization of all monthly birth
ohorts before the age of 3 months, the cost-effectiveness of vac-
ination of each monthly birth cohort before the age of 3 months
as investigated.
.4. Utilities (QALYs)
Quality-of-life losses were included in the model as quality-
djusted life years (QALYs) which were connected to all health
tates. Five health states were distinguished: (1) asymptomatic or
ome-cared RSV-infection (no QALY decrement), (2) RSV-related
ronchi(oli)tis treated at the GP, (3) RSV-related pneumonia or
evere bronchiolitis requiring hospitalization, (4) chronic respira-
ory morbidity following RSV-hospitalization, and (5) death. Both
ALYs and DALYs reported in literature were reviewed [24]. The
utch National Institute for Public Health and the Environment
RIVM) assigns decrements to bronchi(oli)tis of 0.01 DALY, to pneu-



































Incrementa l Ef 
ig. 2. Incremental cost-effectiveness scatterplot for RSV-vaccination versus no vaccinati
nd  D 80,000/QALY (dotted). 30 (2012) 4691– 4700
estimates were obtained by the RIVM by extrapolating daily quality
decrements for a respiratory episode to a 365-day period.
Two papers present an assessment of quality of life after RSV-
related hospital discharge [22,26].  One paper presents actual QALY
scores [26]. In this study, quality-of-life in children, aged 2–4 years,
with a history of preterm birth and RSV-hospitalization were com-
pared with a control group of preterm children without a history
of RSV-hospitalization. The median HUI 2 multi-attribute utility
function was 0.88 in children with a conﬁrmed RSV-infection, as
compared to 0.95 in the control group. This would imply that the
decrease in quality-of-life related to RSV is 0.07. The estimate of
the utility (0.07) is in the same order of magnitude as the DALY
(0.08) decrement for asthma and therefore the most conservative
estimate of 0.07 was  applied in the model.
2.5. Health-care resource use, productivity losses and
corresponding costing
The analysis was performed from a societal perspective includ-
ing both direct medical costs and indirect costs of production losses,
all updated to 2009 (source: Central Bureau of Statistics of the
Netherlands). Health-care costs include costs of GP-visits and costs
of hospitalization (see also Table 1). Over the counter medications,
such as nasal washes, have not been taken into account. The average
costs of a GP-visit were estimated at D 22.17 [27]. Based on a study
by Rietveld et al. the cost of RSV-hospitalization was estimated at
D 3749 [6].  Societal costs included productivity losses by caretakers
as a result of care giving to children suffering from RSV-infections.
The Dutch modeling guidelines were followed and to calculate pro-
ductivity losses, the friction-cost method was used [28]. Compared
to the human capital method, the friction cost method conserva-
tively estimates the productivity losses. It has been estimated that
on average two  parental workdays are lost as the result of an RSV-
related hospitalization [29]. An RSV-related GP visit leads to a loss
of 0.25 workdays. An average hourly wage of D 31.31 was  used for
people in the age group 25–34 years old (young parents) with an
average number of hours per workday of 8 [27]. The resulting ﬁg-
ure of D 251 per workday was  corrected for a productivity elasticity
of 80%. In the sensitivity analysis, the impact of a lower productiv-
ity elasticity was  explored (30–45%) assuming that RSV-episodes
will last no longer than 14 days [27]. In particular, research has
shown that absence from work shorter than 14 days resulted in
productivity losses of only 30–45% of the work time absenteeism.
The price of the vaccine was assumed to be ﬁxed at D 37.50 per
dose plus administration costs of D 5.00 (personal communication,
 600 70 0 800 90 0 100 0 110 0 1200
fectiveness (QALYs)
on. The straight lines represent willingness-to-pay curves of D 20,000/QALY (solid)
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.  Luytjes). It was assumed that vaccination against RSV would be
ncluded in the existing infants NIP.
.6. Outcome measures and cost-effectiveness analysis
The simulation model tracks the cases of RSV, deaths, costs and
ALYs. Summing all the costs, life years and QALYs and conse-
uently calculating the differences for the respective outcomes for
he evaluations without and with vaccination rendered net costs
nd QALYs gained. Dividing the net costs by the health effects
eﬁned the cost-effectiveness ratio. Health effects and cost were
iscounted according to the Dutch guidelines for cost-effectiveness
esearch at 1.5% and 4%, respectively. Cost-effectiveness ratios
CERs) were calculated for routine vaccination using different vac-
ination schedules compared to no vaccination.
.7. Sensitivity analysis
Univariate, scenario and probabilistic sensitivity analyses were
erformed to explore parameter uncertainty. Transition probabil-
ties were inserted as beta distributions and utility decrements as
amma  distributions [30]. Cost-related parameters were inserted
s ﬁxed values when prices were ﬁxed (GP-visit, vaccine-price),
nd as gamma  distribution where they were estimated from a sam-
le (hospitalization costs) or as uniform distributions (productivity
lasticity in productivity loss estimation). Outcome values were
enerated by running the model 10,000 times. In the univariate
ensitivity analyses, all relevant parameters were varied with 25%
o explore the impact of each parameter relative to each other.
. Results
.1. Cost-effectiveness of RSV vaccination
In the current situation in which no vaccine is available, a total
nnual number of 28,738 of GP visits are estimated in children in
he age of 0–1 year. The expected number of hospitalizations in this
cenario is 1623 (95%CI: 356–3635) and the number of RSV-related
eaths is 4.5 (95%CI: 0.96–10.5). The total annual cost to society of
SV disease is D 7.7 million if no vaccination is undertaken (95%CI:
.7–16.7) and the annual disease burden is estimated at 597 QALYs
95%CI: 133–1319). In case all infants would be offered a three-
ose vaccination scheme at the age of 0,1 and 3 months of age, this
ould result in higher costs of D 21.2 million (95%CI: 19.1–25.1),
ut signiﬁcantly lower numbers of hospitalizations (544–95% CI:
5.4–1386) and deaths (1.5–95%CI: 0.25–3.99). Vaccination would
hus result in a cost per QALY of D 34,142 (95% CI: D 211,652–D
7,766).
Table 2 shows the results of various options that can be consid-
red, such as introduction of the vaccination at a somewhat later
tage, for example when infants are 0, 2 and 4 months of age, and
he effects of waning immunity. The results show that most health
ains are obtained when the vaccine is offered as early as possible.
elaying the second and third dose both with one month already
ncreases the ICER to D 40,900 per QALY. Furthermore, when a
aning effect for the vaccine efﬁcacy was taken into account this
bviously negatively affected the incremental cost effectiveness
atio (ICER). Assuming a plateau waning effect in the base case
esulted in a somewhat higher ICER of D 38,544 per QALY and inclu-
ion of a linear waning effect resulted in an ICER of D 52,250 per
ALY. Fig. 2 shows the scatterplot of the incremental cost effec-
iveness ratio for RSV-vaccination versus no vaccination..2. Uncertainty and sensitivity analysis
Univariate sensitivity analyses showed that a number of changes
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he case, for example, when the incidence rates of RSV-related GP-
isits are lowered, when – after a full dosing scheme – a lower
xpected vaccine efﬁcacy is considered or when the time of vacci-
ation is delayed (for example to 0, 2 and 4 months). The disease
urden as such and the distribution of the disease burden over
he age groups considered highly inﬂuence the incremental cost-
ffectiveness ratios. Consideration of an equal distribution of the
P-visits over the age groups of 0–12 and 13–24 months (in the
ase case 86% in the 0–12 months and 14% in the 13–24 months
f age), results in a lower number of GP-visits in the youngest age
roup and this lower incidence results in a higher ICER. When all
ther parameters remain equal, this would result in an ICER of D
7,775.
In the base case, the majority of the disease burden is in chil-
ren under the age of 6 months and this is also conﬁrmed by the
CER when considering a three dose vaccination scheme for infants
hen they are 6, 7 and 8 months of age. This would result in an
ncremental cost effectiveness ratio of around D 287,000 per QALY.
The vaccine price has a moderate inﬂuence on the ICER. A vac-
ine price of D 25 in the base-case analysis results in an ICER of
round D 18,600 per QALY and a vaccine price of D 60 euro result
n an ICER of around D 60,000 per QALY.
The base-case analysis did not include waning immunity for
accine efﬁcacy but when this is included this would also have a
egative impact on the ICER (see for the results Table 2). On the
ther hand there are also a number of changes in model parameters
hat would have a positive impact on the ICER. These include, for
xample, a highly efﬁcacious 2-dose vaccination schedule, offering
he vaccine in a seasonal vaccination schedule, like – for example
 for inﬂuenza, or consideration of out-of-pocket payments.
. Discussion
This paper addresses the challenges which a potential RSV-
accination strategy for children will have to face when it is
onsidered for inclusion into national vaccination programs. In
ddition to the previous study by Bos et al. [21], our model includes
pdated estimates on the burden of RSV-disease from Jansen et al.
3,4] and it also includes quality of life data. Because RSV-vaccines
re still in development, few clinical studies are available and, in
he Netherlands as well as elsewhere, large-scale clinical trials are
ot expected before 2012. Based on (i) available epidemiological
ata in children and on (ii) a number of assumptions that had
o be made in the absence of, for example, vaccine efﬁcacy data,
he potential cost-effectiveness of RSV-vaccination of children has
een estimated. The base-case analysis showed a potential for RSV-
accination to be cost-effective according to current standards.
ur study shows that the continuous interest in development of
ffective RSV-vaccines is relevant from a health-economic perspec-
ive, which is important for the decision-making process in the
etherlands and elsewhere. As soon as more data become avail-
ble, for example from vaccine trials, the model will be re-analyzed
n order to review the impact of the updated evidence.
Taking the current model into account, our study has several
imitations.
First, the current Markov model is a static model, assum-
ng a constant force of infection and no herd-immunity effects.
ncreasingly, dynamic models are being used and advocated in cost-
ffectiveness analyses of vaccination programs [31]. These models
nable the analysis of herd-immunity effects, possible age shifts in
pidemiology and changing forces of infection, but are generally
ighly complex and require extensive information to parameterize
hem. Therefore, in the present situation, with as yet only limited
vailable information on the characteristics of a potential RSV-
accine, the initial use of a static approach is justiﬁed. A dynamic 30 (2012) 4691– 4700
approach is warranted when further information on the efﬁcacy of
RSV-vaccination becomes available from epidemiological studies,
subsequent clinical trials and observational studies on the conse-
quences of RSV-vaccination in routine daily practice [32].
Second, in databases symptomatic RSV infections are registered
whereas it is known that most RSV infections are asymptomatic
infections which also lead to (partial) protection. The effect these
infections have on the total disease burden is unknown but
expected to be signiﬁcant due to the duration of the illness, the
costs involved in it; both direct medical cost as well as productivity
losses for the parents. The exclusion of these infections from the
model is expected to lead to an underestimation of the potential
beneﬁt of vaccination.
Third, epidemiological data show that around 90% of infants
experience their ﬁrst RSV infection before the age of two  and that
the incidence of RSV related hospitalizations and LRTI’s decreases
with age. The highest disease burden is observed in children 1–6
months of age. It is suggested that there is little protective effect
after the ﬁrst infection, although there are indications that the
primary infection is the most severe and that the course of sub-
sequent infections is milder [3,4]. The epidemiological data used
in the model only include the primary infection and therefore
the data are all independent observations. Taking only the pri-
mary symptomatic infection into account is expected to lead to an
underestimation of the total disease burden but a straightforward
extrapolation based on a higher number of infections per person is
not possible due to the milder course of the disease for subsequent
infections [3,4].
Fourth, the epidemiological study that has been the primary
source of the epidemiological data in the model considered the
excess mortality due to RSV and did not report any signiﬁcant
excess mortality in the study sample. Other studies report a mortal-
ity rate of between 0.5 and 8 per 100,000 infants. Due to the variety
of mortality data reported, the inﬂuence of this model parameter is
reviewed critically in the sensitivity analyses. Because of the signif-
icant inﬂuence it has on the incremental cost-effectiveness ratio, it
is important to gather long-term, detailed national mortality data
on RSV.
Fifth, it is unknown whether hospitals regularly test for RSV-
infection when very young infants are brought into the hospital
with respiratory-tract illness. Therefore, missing cases are certainly
expected from these registries, and it will also remain a challenge in
the future to obtain reliable national hospital data on infants with
an RSV-infection.
Lastly, the model did not assess the potential cost-effectiveness
of RSV-vaccination when only high-risk groups or groups which
are currently receiving prophylactic therapy (palivizumab) are tar-
geted. Assuming that 1800 infants (1% of the birth cohort) receive
prophylactic therapy at a cost of D 3645 euro per person (for
ﬁve injections), we  estimate that the yearly RSV-related costs of
palivizumab amount to 6.6 million euro in the Netherlands. This is
highly signiﬁcant, taking into account that the total RSV-related
costs in the absence of vaccination are estimated at 7.7 million
euro, of which hospital-related costs are around 3.7 million euro
(48%). Considering that part of the infants currently receiving pro-
phylactic therapy might shift to vaccination might further improve
cost-effectiveness of vaccination.
The results of the study show that there is a need for promoting,
improving and extending the European RSV surveillance system.
Future research might focus on the potential effect of clustering
because of the possibilities for subsequent infections. To obtain a
better overview of the total burden of RSV-disease, it would be
valuable to have a detailed insight in the proportion of children
experiencing one or more RSV-infections. Also, more research is
needed to estimate the protective effect of a primary RSV-infection.
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f indirect protection of young infants when older infants/siblings
re immunized. Furthermore, the use of a dynamic model should
e considered when additional information on these aspects of
SV-infection and -vaccination becomes available. An alternative
accination strategy that might be considered is the immunization
f pregnant women in order to provide a degree of passive pro-
ection to the babies via transplacental immunity. Antibodies are
he main mediators of protective immunity (which is the case with
SV) and therefore maternal antibodies will also protect the baby.
Finally, it will be of interest to review the burden of RSV-disease
nd the cost-effectiveness of RSV-vaccination among the elderly.
Decision-makers usually review all available data. However,
oon after a vaccine is available on the market, mainly efﬁcacy
ata from randomized clinical trials can be considered. The effect
f vaccination in an uncontrolled environment has to be shown
fterwards, including potential herd-immunity effects. The results
f this study indicate that depending on vaccination efﬁcacy,
SV-vaccination might be more cost-effective than the previously
utch pneumococcal vaccination program with the seven-valent
neumococcal vaccine [32]. Cost-effectiveness analyses for the
neumococcal vaccine have recently been updated and resulted
n less favorable ICERs than the ICERs that were considered when it
as decided to include the vaccine in the NIP. At the same time, the
esults also show that RSV-vaccination might be less cost-effective
han other potential vaccination programs which are not yet imple-
ented in the Netherlands. It is important to keep in mind that,
mong others, the quality of epidemiological data, the disease bur-
en, the availability of alternative treatments for a disease, the
elationship with the compliance to the other vaccines included
n the national scheme are all important parameters to consider.
rgo, cost-effectiveness is only one of many aspects to be taken
nto account by decision-makers when they consider a particular
accination for inclusion in the national immunization scheme.
ppendix A.
This appendix describes the background of the probabilities for
SV-related health care utilization that are presented in Table 1 of
he main text in more detail in order to justify the choices made
Data used in the economic model).  The overall strategy was to build
ur model on incidence data estimated for the Netherlands. Avail-
ble international data was presented to reﬂect on the choices
able A1
verview of the literature regarding GP visits caused by RSV.
Paper Country Period Study type Study size 
[15] Netherlands n.s. n.s. n.s. 
[3]  Netherlands 1997–2003 Retrospective 47,000












[35]  USA n.s. n.s. n.s. 
SV-H: Hospitalization for RSV.
SV-GP: GP visit attributed to RSV infection.
SV-LRTI-GP: GP visit for lower respiratory tract infection (bronchiolitis or pneumonia) a
SV-URTI-GP: GP visit for upper respiratory tract infection (bronchiolitis or pneumonia) a
.s.:  Not speciﬁed. 30 (2012) 4691– 4700 4697
which were made when national data was lacking, available data
from other countries were used in the model.
A.1. GP visits related to RSV
Table A1 summarizes the literature search performed assessing
the RSV-associated primary health care burden. Five studies were
included in the research, two  studies retrospectively looked at the
RSV ﬁgures and two  studies used a prospective study design and
three studies were performed in the Netherlands. In addition, one
report was  available from the Dutch National Institute for Public
Health and the Environment but unfortunately no references were
used in this document. The data show considerable variation in the
estimates. Notably, the estimate by the Dutch National Institute
for Public Health and the Environment [15] is much lower than the
estimate for the Netherlands provided by Jansen et al [4].  The study
of Jansen is valued higher than the report by the institute for public
health and the environment due to the fact that no study design and
references were available for the report of the later institute and the
study from Jansen covers an eight-year period which reduces the
risk of outliers (e.g. regression to the mean). RIVM estimates the
number of hospitalizations at 209 per 100 K <60 m/o  (see below). If
the number of GP visits would be 413 per 100 K <60 m/o, this would
imply that >50% of RSV-cases presented at the GP is referred for hos-
pital admission, which we consider to be an unlikely high estimate.
In their conservative scenario, Jansen et al. [4] estimate the num-
ber of GP visits at 9400 GP visits per 100,000 children under 24 m/o.
The proportion of the under 12 months olds in this ﬁgure is not pro-
vided and could not be retrieved from the available data. When the
same age distribution as for hospitalizations is applied (84–86% of
total hospitalizations occur in the age groups 0–12 months and the
remainder in the age group 13–24 months), the number of GP vis-
its in the age group 0–12 months of age would approximately be
16,000 per 100 K per year (0.85 × (9401 + 9401) = 16,000. Assum-
ing that the GP visits are equally distributed among the age groups
0–12 months and 13–24 months, the number of GP visits under
12 months would be 9400 per 100 K per year. These two  scenarios
were tested in the model.A.2. Hospitalizations related to RSV
Table A2 summarizes the literature search performed on hos-
pitalizations related to RSV. The studies are performed in the USA,
Age group Clinical event Incidence per 100 K/y
<60 m/o  RSV-GP 413




nnaire 9–537 d/o; median 79 RSV-GP n.s. Average of 2
RSV-GP visits per
RSV-H
 305 <12 m/o  RSV-GP n.s. RSV-GP in 30% of 31
single-pathogen RSV
,000 <12 m/o  RSV-GP 12,000
<24 m/o  RSV-ED 6440
ttributed to RSV infection.
ttributed to RSV infection.
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Table A2
Overview of literature regarding RSV-related hospitalizations.
Paper Country Period Study type Study size Age group Clinical event Incidence per 100 K/y
[15] Netherlands n.s. n.s. n.s. <60 m/o RSV-H 209
Netherlands Statistics, 2009 Netherlands 2006–2007 Registration National <12 m/o LRTI-H 2006: 1932 2007: 2322
Netherlands Statistics, 2009 Netherlands 2006–2007 Registration National <12 m/o URTI-H 2006: 3578 2007: 3507
[4] Netherlands 1997–2003 Retrospective 47,000 <12 m/o RSV-LRTI-H Peri-seasonal: 870
Summer: 1063
<24 m/o RSV-URTI-H Peri-seasonal: 34.7
Summer: 90.6
[36] UK 2000–2001 Retrospective 613 <12 m/o RSV-H 1906
[37] UK  1993–1996 Retrospective n.s. <12 m/o RSV-H 2440
[38] USA 2000–2004 Retrospective n.s. <6 m/o RSV-H 1700
7–12 m/o  RSV-H 500
[39,40] USA  1989–1993 n.s. n.s. <12 m/o RSV-H 3000
[40] USA  n.s. n.s. n.s. <12 m/o RSV-H 1290–3000
[41] USA 2000–2001 Prospective
surveil-
lance
812 <6 m/o RSV-H 1850
7–12 m/o  RSV-H 740
<12 m/o RSV-H 1290
[42]  USA 1997–1999 Retrospective 297,684 records <12 m/o RSV-H 2520
[43]  Denmark 1995–1996 Retrospective 459 records <6 m/o RSV-H 3400
[44]  Germany 1996–1999 Prospective
surveillance
1241 samples <12 m/o RSV-H 1214
RSV-H: Hospitalization for RSV infection.
RSV-URTI-H: Hospitalization for upper respiratory tract infection caused by RSV.
R





















OSV-LRTI-H: Hospitalization for lower respiratory tract infection caused by RSV.
RTI-H, URTI-H: Hospitalization for lower, upper respiratory tract infection, etiolog
.s.:  not speciﬁed
he UK and the Netherlands, they cover different study periods and
se various study design such as registration, retrospective cohort
tudies and two used a prospective surveillance study design. The
ge groups generally included in the studies are either below 12
r below 24 months of age and the main outcome parameter
s RSV-hospitalization. Since the latest studies are performed in
he Netherlands, they also cover either the total population or
ave included a very signiﬁcant part of the population the model
ill make use of the available Dutch estimates. RIVM estimates
he number of RSV-hospitalizations at 209 per 100 K <60 m/o. If
e apply the age distribution estimated by Jansen to this ﬁgure,
79–84% of RSV-related hospitalizations in <12 m/o), we  arrive at an
stimate of 826–878. This estimate is quite in line with the conser-
ative estimate by Jansen et al. of 901 hospitalizations per 100 K <12
onths old, which was used as the default value in the model [4].
.3. Mortality related to RSVTable A3 summarizes the results of the literature search per-
ormed on the mortality of RSV. Only a very small number of
tudies looked at RSV mortality, the majority of studies used a
able A3
verview of literature regarding RSV-related mortality.
Paper Country Period Study type Stu
[4] Netherlands 1997–2003 Retrospective 47
[15]  Netherlands n.s. n.s. n.s
[14]  UK 1989–1999 Retrospective Na
[2]  USA n.s. Review n/
[1]  Netherlands n.s. Review n/
[45] USA 1976–1999 Retrospective n.s
[6] Netherlands 1996–1998 Retrospective cohort 24
[46]  USA 1993–1995 Retrospective 10speciﬁed.
retrospective study design and did not ﬁnd signiﬁcant mortality
rates. Mortality was primarily observed in the youngest children,
age <12 months and the study with the largest study sample was
performed in the Netherlands. Estimates range from 0.03 per
100,000 to 5.3 per 100,000 population. RIVM reports a mortality
rate of 0.03 per 100,000 for the total population corresponding
to a total number of 4.5 deaths per year due to RSV. However, no
reference was  made to an article for this ﬁgure. Assuming that all
mortality occurs in the youngest age group, this estimate would
equal a mortality of 2.7 per 100 K <12 m/o  (the size of the birth
cohort in the Netherlands is approximately 180,000). This ﬁgure is
however not conﬁrmed by other Dutch papers, where no mortality
was found [4,6]. Fleming and colleagues estimated the mortality
rate for the UK at 2.9 per 100,000 and Howard and colleagues was
at the high end with a mortality rate of 5.3 per 100,000 for the
USA.
For the base case analysis, taking into account the variability
in mortality data, the model uses an average of 2.5 per 100,000
population for the 0–12 months of age group. The inﬂuence the
mortality rate has on the outcomes of the study will be looked at
using sensitivity analyses.
dy size Age group Mortality per 100 K/y
,000 <12 m/o  none
. Population n.s. 0.03
tional <12 m/o  2.9
a n.s. n.s. 0.5–2% mortality in RSV-H
a n.s. n.s. <1% mortality in acute bronchiolitis
. <12 m/o  3.1
69 RSV-H <12 m/o  none
,767 RSV-H <4 yrs of age n.s. 5.3(390 deaths)
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Table A4
Overview of literature regarding age and seasonal distribution of RSV-infections.
Paper Country Period Study type Study size Clinical event Age/seasonal distribution
[5,6] Netherlands 1996–1998 Retrospective 2469 RSV-H RSV-H Cumulative distribution of cases: <3 m/o  38%,
<6  m/o  68%, <9 m/o 82%, <12 m/o 90%.
[4]  Netherlands 1997–2003 Retrospective 47,000 <12 m/o  Cumulative distribution of cases: <12 m/o  79–84%
[41]  USA 2000–2001 Prospective 812 RSV-H Cumulative distribution of cases: <6 m/o  56%,
<12 m/o  78%
[46]  USA 1993–1995 Retrospective 10,767 RSV-H RSV-H 70% of all RSV-H <12 m/o
[5,6,46] Netherlands 1996–1998 Retrospective 2469 RSV-H RSV-H O (4%) N (23%) D (33%) J (21%) F (11%) M (6%) A
(2%)
[47]  Netherlands 1992–2003 Retrospective 15 RSV-ICU RSV-ICU N = 15. O (1) N (1) D (6) J (4) F (2) M (1) A (0)
RSV-H: Hospitalization for RSV infection.
RSV-ICU: Treatment in Intensive Care Unit for RSV infection.
The letters O, N, D, J, F, M and A stand for the months of the RSV season, starting in October.
Table A5
Overview of literature regarding RSV-related chronic respiratory symptoms.
Paper Country Period Study type Study size Age group Clinical event Risk
[12] n/a n/a Review n.s. n.s. Recurrent wheezing
after RSV-H
42–71% until 13 y/o
[22]  Netherlands 1999–2002 Prospective 140 RSV-H start <12 m/o  followed 3 y Wheezing after RSV-H 55% after 3 m 10% 18 m
[11]  n/a 1978–1998 Review n.s. start <12 m/o  followed 10 y Wheezing after RSV-H 40% until 5 y after
RSV-H (11% control)
[1] n/a n/a Review n/a 7–11 y/o Recurrent episodes of
asthma
>50% of ex-RSV-H


















i[48]  n.s. 1980–1997 Prospective
birth cohort
207 RSV-URTI 
.4. Age and seasonal distribution of RSV-infections
Table A4 summarizes the literature search performed on hospi-
alizations related to RSV speciﬁcally looking at age and seasonal
istributions of RSV infections. All studies indicate that the majority
f all RSV hospitalizations (70–90%) occur in infants <12 m/o, and
hat the largest disease burden falls upon <6 months olds which is
n line with the epidemiology of RSV The majority of studies used
 retrospective study design and a study period of 3 years was very
ommon. One study included a much longer study period but only
ooked at the cases treated in the ICU and one retrospective cohort
tudy looked at all RSV related cases including hospitalizations.
enerally, it is expected that the data presented on hospitalized
ases in infants is reliable as it is one of the most likely causes for
ospitalization in infants and is therefore regularly performed. In
he model, estimates of RSV hospitalizations by Rietveld et al. [6]
nd Jansen et al. [4] are used. Both authors performed their stud-
es in the Netherlands. The estimate was included in the model as




a multinomial Dirichlet distribution. The seasonal distribution of
cases used in the model was also derived from Rietveld and also
inserted as a multinomial Dirichlet distribution in our model. In
Figs. 3 and 4 the attack rate per calendar month and the attack rate
per month during the ﬁrst year of life is presented. The information
from both ﬁgures is used in the model to calculate the attack rate
per age group per month.
A.5. Chronic respiratory morbidity
Table A5 summarizes the literature search performed on the
occurrence of sequelae after severe RSV infection. There is a wide
range of estimates regarding the proportion of former RSV cases
that suffer from chronic respiratory symptoms, the duration of
symptoms, and the severity of these symptoms. But also the
study types differ, study sizes are relatively small and the clinical
events evaluated are not always similar. However, despite these
differences, most studies ﬁnd a gradual decrease in symptoms as
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hildren progress into school age. As indicated in the Methods
ection of the paper, due to the uncertainty regarding the causal
elationship, the occurrence of sequelae was only included in the
odel as an alternative scenario. Assuming a baseline disease risk
f recurrent wheezing of approximately 10% [11], an excess risk of
0% for recurrent wheezing was taken into account in the model,
ith an expected duration of symptoms of 5 years.
eferences
[1] Kimpen JL. Prevention and treatment of respiratory syncytial virus bronchiolitis
and  postbronchiolitic wheezing. Respiratory Research 2002;3(Suppl 1), p.S40-
5.
[2] Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354(9181):
847–52.
[3] Jansen AG, et al. Rate-difference method proved satisfactory in estimating
the inﬂuenza burden in primary care visits. Journal of Clinical Epidemiology
2008;61(8):803–12.
[4]  Jansen AG, et al. Inﬂuenza- and respiratory syncytial virus-associated mortality
and hospitalisations. European Respiratory Journal 2007;30(6):1158–66.
[5] Rietveld E, et al. Anticipated costs of hospitalization for respiratory syncytial
virus infection in young children at risk. Pediatric Infectious Disease Journal
2004;23(6):523–9.
[6] Rietveld E, et al. Hospitalization for respiratory syncytial virus infection in
young children: development of a clinical prediction rule. Pediatric Infectious
Disease Journal 2006;25(3):201–7.
[7] Assink MD,  et al. Excess drug prescriptions during inﬂuenza and RSV seasons
in  the Netherlands: potential implications for extended inﬂuenza vaccination.
Vaccine 2009;27(7):1119–26.
[8] Hall CB, et al. Immunity to and frequency of reinfection with respiratory syn-
cytial virus. Journal of Infectious Diseases 1991;163(4):693–8.
[9] Weber A, Weber M,  Milligan P. Modeling epidemics caused by respiratory syn-
cytial virus (RSV). Mathematical Biosciences 2001;172(2):95–113.
10] Fleming DM,  Elliot AJ, Cross KW.  Morbidity proﬁles of patients consulting dur-
ing inﬂuenza and respiratory syncytial virus active periods. Epidemiology and
Infection 2007;135(7):1099–108.
11] Kneyber MCJ, et al. Long-term effects of respiratory syncytial virus (RSV) bron-
chiolitis in infants and young children: a quantitative review. Acta Paediatrica
2000;89(6):654–60.
12] Bont L, Aalderen WM,  Kimpen JL. Long-term consequences of respiratory syncy-
tial virus (RSV) bronchiolitis. Paediatric Respiratory Reviews 2000;1(3):221–7.
13] Bloemers BL, et al. High incidence of recurrent wheeze in children with down
syndrome with and without previous respiratory syncytial virus lower respi-
ratory tract infection. Pediatric Infectious Disease Journal 2010;29(1):39–42.
14] Fleming DM,  Pannell RS, Cross KW.  Mortality in children from inﬂuenza and
respiratory syncytial virus. Journal of Epidemiology and Community Health
2005;59(7):586–90.
15] RIVM. RSV-infectie (respiratoir syncytiaal virus). 2009, [Accessed
on: 29-6-2009]; Available from: www.rivm.nl/cib/infectieziekten-
A-Z/infectieziekten/RSV infectie@28respiratoir-
syncytiaalvirus@29/index.jsp#index 6.
16] Committee for Pharmaceutical Help, CVZ. Pharmaco economic eval-
uation of palivizumab. [Accessed on: 28-9-2009]; Available from:
http://www.cvz.nl/binaries/live/CVZ Internet/hst content/nl/documenten/cfh
rapporten/2006/rpt0609+palivizumab-Synagis.pdf.
17] Kim HW,  et al. Respiratory syncytial virus disease in infants despite prior
administration of antigenic inactivated vaccine. American Journal of Epidemi-
ology 1969;89(4):422–34.
18] Delgado MF,  et al. Lack of antibody afﬁnity maturation due to poor Toll-like
receptor stimulation leads to enhanced respiratory syncytial virus disease.
Nature Medicine 2009;15(1):34–41.
19] Waris ME,  et al. Respiratory synctial virus infection in BALB/c mice previously
immunized with formalin-inactivated virus induces enhanced pulmonary
inﬂammatory response with a predominant Th2-like cytokine pattern. Journal
of  Virology 1996;70(5):2852–60.
20] Acedo L, et al. Mathematical modelling of respiratory syncytial virus (RSV):
vaccination strategies and budget applications. Epidemiology and Infection
2010;138(6):853–60.
21] Bos JM,  et al. The use of health economics to guide drug development decisions:
determining optimal values for an RSV-vaccine in a model-based scenario-
analytic approach. Vaccine 2007;25(39-40):6922–9.
[
[ 30 (2012) 4691– 4700
22] Bont L, et al. Impact of wheezing after respiratory syncytial virus infec-
tion on health-related quality of life. Pediatric Infectious Disease Journal
2004;23(5):414–7.
23] Sigurs N, et al. Severe respiratory syncytial virus bronchiolitis in infancy and
asthma and allergy at age 13. American Journal of Respiratory and Critical Care
Medicine 2005;171(2):137–41.
24] Tarride JE, et al. A review of health utilities across conditions common in pae-
diatric and adult populations. Health Qual Life Outcomes 2010;8:12.
25] RIVM. Sterfte, ziekte en ziektelast voor 56 geselecteerde aandoeningen. Nation-
aal Kompas Volksgezondheid. 2003, [Accessed on: 2009]; Available from:
http://www.rivm.nl/vtv/object document/o4237n16906.html.
26] Greenough A, et al. Health care utilisation of prematurely born: preschool
children related to hospitalisation for RSV infection. Archives of Disease in
Childhood 2004;89(7):673–8.
27] Oostenbrink JB, Bouwmans CAM, Koopmanschap MA,  Rutten FHH. Handleiding
voor kostenonderzoek. Methoden en standaard kostprijzen voor economische
evaluaties in de gezondheidszorg [Guidelines for costing research, methods
and standardized prices for economic evaluations in health care], ed. C.v.Z.H.I.
Board. 2004: CVZ, Diemen, the Netherlands.
28] Koopmanschap MA,  et al. The friction cost method for measuring indirect costs
of  disease. Journal of Health Economics 1995;14(2):171–89.
29] Miedema CJ, et al. Medical consumption and socioeconomic effects of infection
with respiratory syncytial virus in The Netherlands. Pediatric Infectious Disease
Journal 2001;20(2):160–3.
30] Briggs A, Claxton K, Sculpher M.  Decision modelling for health economic eval-
uation. Oxford: Oxford University Press; 2006.
31] Jit M,  Brisson M.  Modelling the epidemiology of infectious diseases for decision
analysis: a primer. Pharmacoeconomics 2011;29(5):371–86.
32] Rozenbaum MH, et al. Cost effectiveness of pneumococcal vaccination among
Dutch infants: economic analysis of the seven valent pneumococcal conju-
gated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ
2010;340:c2509.
33] Greenough A, et al. School age outcome of hospitalisation with respiratory syn-
cytial virus infection of prematurely born infants. Thorax 2009;64(6):490–5.
34] van der Zalm MM,  et al. Respiratory pathogens in respiratory tract illnesses
during the ﬁrst year of life: a birth cohort study. Pediatric Infectious Disease
Journal 2009;28(6):472–6.
35] Bourgeois FT, et al. Relative impact of inﬂuenza and respiratory syncytial virus
in  young children. Pediatrics 2009;124(6):e1072–80.
36] Nicholson KG, et al. Rates of hospitalisation for inﬂuenza: respiratory syncytial
virus and human metapneumovirus among infants and young children. Vaccine
2006;24(1):102–8.
37] Deshpande SA, Northern V. The clinical and health economic burden of respi-
ratory syncytial virus disease among children under 2 years of age in a deﬁned
geographical area. Archives of Disease in Childhood 2003;88(12):1065–9.
38] Hall CB, et al. The burden of respiratory syncytial virus infection in young
children. New England Journal of Medicine 2009;360(6):588–98.
39] Boyce TG, et al. Rates of hospitalization for respiratory syncytial virus infection
among children in medicaid. Journal of Pediatrics 2000;137(6):865–70.
40] Lee MS,  Walker RE, Mendelman PM.  Medical burden of respiratory syncytial
virus and parainﬂuenza virus type 3 infection among US children, implications
for  design of vaccine trials. Human Vaccines 2005;1(1):6–11.
41] Iwane MK,  et al. Population-based surveillance for hospitalizations associated
with respiratory syncytial virus: inﬂuenza virus, and parainﬂuenza viruses
among young children. Pediatrics 2004;113(6):1758–64.
42] Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitaliza-
tions: 1997 to 1999. Pediatric Infectious Disease Journal 2002;21(7):629–32.
43] Kristensen K, et al. Epidemiology of respiratory syncytial virus infection
requiring hospitalization in East Denmark. Pediatric Infectious Disease Journal
1998;17(11):996–1000.
44] Weigl JA, Puppe W,  Schmitt HJ. Incidence of respiratory syncytial virus-positive
hospitalizations in Germany. European Journal of Clinical Microbiology and
Infectious Diseases 2001;20(7):452–9.
45] Thompson WW,  et al. Mortality associated with inﬂuenza and respiratory syn-
cytial virus in the United States. Journal of the American Medical Association
2003;289(2):179–86.
46] Howard TS, et al. Respiratory syncytial virus pneumonia in the hospi-
tal  setting: length of stay, charges, and mortality. Journal of Pediatrics
2000;137(2):227–32.47] Verboon-Maciolek MA,  et al. Clinical and epidemiologic characteristics of viral
infections in a neonatal intensive care unit during a 12-year period. Pediatric
Infectious Disease Journal 2005;24(10):901–4.
48] Stein RT, et al. Respiratory syncytial virus in early life and risk of wheeze and
allergy by age 13 years. Lancet 1999;354(9178):541–5.
